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Background: Src is involved in cancer invasion and metastasis. AZD0424, an oral inhibitor of Src and ABL1, has shown evidence of
anti-tumour activity in pre-clinical studies.
Methods: A phase Ia, dose escalation study was performed to assess the safety of continuous oral dosing with AZD0424 in
advanced solid tumours. Secondary objectives included investigation of AZD0424 pharmacokinetics, effect on Src activity using
markers of bone turnover, and anti-tumour activity.
Results: 41 patients were treated; 34 received AZD0424 once-daily at doses ranging from 5mg to 150mg, and 7 received 40mg
bi-daily 41.5% of patients experienced at least one AZD0424-related adverse event that was Grade 3–5 in severity, with patients
treated at doses above 60mg per day experiencing multiple treatment-related toxicities. The most commonly observed AZD0424-
related adverse events were nausea, fatigue, anorexia and alopecia. Cmax and AUC increased linearly with dose and the
mean±standard deviation t1/2 was 8.4±2.8 h. Clear evidence of Src target inhibition was seen at doses X20mg per day. No
responses were observed and 7 patients (17.1%) achieved stable disease lasting 6 weeks or more.
Conclusions: AZD0424 displayed no evidence of efficacy as monotherapy despite a clear pharmacodynamic effect. Further
evaluation of AZD0424 monotherapy in patients with solid tumours is not recommended.
AZD0424 is an inhibitor of the proto-oncogenic non-receptor
tyrosine kinases Src and ABL1 which have been found to be
dysregulated in cancer. Src is expressed at low levels in the majority
of cell types and is implicated in pathways regulating bone
metabolism, proliferation, survival, migration and angiogenesis
(Aleshin and Finn, 2010). It is known to play a role in the
regulation of cell invasion and metastasis in cancer, and elevated
Src expression and activity is seen in several human tumour types
including carcinomas of the breast (Egan et al, 1999), lung
(Mazurenko et al, 1992) and colon (Bolen et al, 1987). In addition,
Src expression has been correlated with advanced malignancy and
poor prognosis in a variety of cancers (Wheeler et al, 2009a)
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including colorectal carcinoma (Aligayer et al, 2002) and
osteosarcoma (Hu et al, 2015). There is also evidence that
upregulation of Src expression and/or signalling is associated with
resistance to many classes of anti-cancer drugs (Mayer and Krop,
2010) including those targeted against HER-2 (Peiro et al, 2014)
and EGFR (Wheeler et al, 2009b), and that combination of Src
inhibitors with such agents may reverse or prevent the occurrence
of such resistance (Zhang et al, 2011). While more commonly
known for its role in haematological malignancies, ABL1 kinase
has also been identified as a potential target with relevance in solid
tumours. For example, ABL kinases are constitutively activated in
invasive breast cancer cell lines, downstream of deregulated ErbB
receptors and Src kinases (Srinivasan and Plattner, 2006). It has
also been shown that activation of ABL kinases can promote breast
cancer cell invasion, and treatment of cells with the ABL1 kinase
inhibitor, imatinib, markedly inhibits cell motility.
Accordingly, Src and ABL1 are potentially attractive targets for
therapeutic intervention, and this has led to the clinical develop-
ment of Src inhibitors such as saracatinib (Baselga et al, 2010), and
dual Src/ABL1 inhibitors, including dasatinib (Yu et al, 2009) and
bosutinib (Daud et al, 2011). While there has been efficacy in
haematological malignancies, only occasional responses have been
seen with these agents as monotherapy in solid tumours.
Combination studies have also proven largely disappointing with
no significant improvements in progression-free survival or overall
survival seen in placebo-controlled trials of paclitaxel with
saracatinib in platinum-resistant ovarian cancer (McNeish et al,
2014), or cediranib plus saracatinib in relapsed metastatic renal cell
cancer (Powles et al, 2016). A large phase III trial of dasatinib plus
docetaxel and prednisolone in patients with prostate cancer was
also negative (Araujo et al, 2013) as was a smaller phase II study of
cediranib alone vs cediranib in combination with dasatinib in
docetaxel-resistant, castration-resistant prostate cancer (Spreafico
et al, 2014). A lack of biomarkers, such as level of expression or
activation of Src, to identify patients most likely to respond to
therapy and contradictory effects of non-selective inhibitors upon
different members of Src family kinases (SFKs), have been
identified as potential issues underlying this lack of efficacy
(Elias and Ditzel, 2015).
AZD0424 is an orally available, potent (IC50 approximately
4 nM) inhibitor of the Src and ABL1 kinases, with additional
activity against other SFK members including Yes and Lck (Cancer
Research UK Centre for Drug Development, 2015). Its chemical
structure is displayed in Figure 1. AZD0424 exhibits considerable
selectivity for Src-Abl1 kinases vs VEGFR-2 (4933-fold) and
C-terminal Src tyrosine kinase (CSK) (4448-fold), a negative
regular of Src kinase. While both dasatinib and bosutinib potently
inhibit Src-Abl kinases (Davis et al, 2011), they have a relatively
low selectivity for SFKs over CSK (approximately 5-fold and 30-
fold respectively). An extensive kinase profile of Saracatinib has not
been published; however, the available data suggests it has a similar
prolife to that of AZD0424 (although the latter compound is
somewhat more potent at inhibiting ABL1) (Green et al, 2009).
In vitro, AZD0424 demonstrated potent inhibition of prolifera-
tion of mouse fibroblasts engineered to over-express activated Src
kinase (c-SRC 3T3) and also inhibited proliferation of growth
factor stimulated human umbilical vein endothelial cell cultures.
However, inhibition of proliferation in a diverse panel of non-
engineered human tumour cell lines was generally poor. In
contrast, AZD0424 produced potent inhibition of migration of
human tumour cells, with evidence of inhibition of phosphoryla-
tion of the Src kinase substrate paxillin, suggesting anti-tumour
effects may be due to inhibition of Src-mediated adhesion and
motility signalling pathways. In vivo, AZD0424 produced moderate
anti-tumour growth effects in rats bearing human Calu-6 lung
tumour xenografts while profound, dose-dependent inhibition of
tumour growth was seen in immunocompromised rats bearing
subcutaneously growing c-Src 3T mouse xenografts. In pre-clinical
studies, AZD0424 produced toxic effects in the gastrointestinal,
haematopoietic and lymphoid systems, with gastrointestinal
toxicity being dose limiting in both rat and dog. Hypotension
and reflex tachycardia were also observed in both species. Bone
turnover was found to be reduced with resultant increases observed
in trabecular and cortical bone.
Based on the pre-clinical anti-tumour activity and acceptable
toxicity profile, a first-in-man, phase Ia dose escalation study of
AZD0424 was performed. The primary objective was to determine
a recommended dose for AZD0424 as a single agent, by
establishing the maximum tolerated dose (MTD) and assessing
the safety profile of AZD0424 when given orally. The secondary
objectives were to investigate the PK of AZD0424, its effect on
markers of bone turnover (as proof of Src inhibition and
achievement of a biologically active dose), and to explore possible
anti-tumour activity in patients with advanced solid tumours.
PATIENTS AND METHODS
Patient eligibility. PatientsX18 years of age with histologically or
cytologically proven solid tumours refractory to conventional
treatment, or for which no suitable conventional therapy existed at
the time, were eligible for the study. Other inclusion criteria
included a life expectancy of at least 12 weeks, World Health
Organisation (WHO) performance status of 0–2 and the following
haematological and biochemical indices: haemoglobin
X9.0 g dl 1; absolute neutrophil count (ANC) X1.5 109 l 1;
platelet countX100 109 l 1; serum bilirubinp1.5 upper limit
of normal (ULN); alanine amino-transferase (ALT) and aspartate
aminotransferase (AST) p2.5ULN and calculated creatinine
clearance X50mlmin 1. All patients gave written informed
consent in accordance with institutional guidelines before study
treatment.
Patients were excluded from the study if they had symptomatic
brain metastases, current significant or recent prior history of
cardiac disease, QT interval prolongation (4480ms, corrected for
heart rate), hypotension (defined as systolic blood pressure
o90mmHg) or other relevant clinical conditions such as active
infection. Radiotherapy (except for palliative reasons), endocrine
therapy, immunotherapy, chemotherapy or other investigational
agents were not permitted during the 4 weeks before treatment
with AZD0424 (6 weeks for nitrosoureas and mitomycin-C).
Study design. CRUKD/07/61 was an open-label, first-in-human,
phase I study. The starting dose of AZD0424 was 5mg orally once
daily (o.d.), based on pre-clinical studies which suggested a
minimum anticipated biological effect level (MABEL) in a 70 kg
human of approximately 5mg. This dose was also less than one
tenth of the maximum tolerated dose in rat scaled to man (17mg).
Treatment cycles consisted of 28 days of continuous AZD0424
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Figure 1. Structural formula of AZD0424 (7-[2-(4-Acetylpiperazin-1-
yl)ethoxy]-N-(6-chloro[1,3]dioxolo[4,5-b]pyridin-7-yl)-5-
isopropoxyquinazolin-4-amine).
Phase I study of AZD0424 in advanced solid tumours BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.484 771
administration, and treatment was to be continued until disease
progression, patient withdrawal or unacceptable toxicity.
Patients were recruited initially into single patient cohorts until
Grade 2 toxicity that was probably or possibly related to AZD0424
was observed in Cycle 1. Once Grade 2 drug-related toxicity was
observed, that cohort was to be expanded to three patients and a
‘3þ 3’ dose escalation scheme initiated for the current and
subsequent cohorts. Escalation of 100% of the dose between
cohorts was permitted until a dose of 40mg was reached, after
which dose increments of up to 50% were allowed.
Dose-limiting toxicities (DLTs) were defined as adverse events
(AEs) that were highly probably or probably related to AZD0424
during the first cycle of treatment including: Grade 4 neutropenia
X5 days; febrile neutropenia with ANCo1.0 109 l 1; infection
(documented clinically or microbiologically) with Grade 3 or 4
neutropenia (ANCo1.0 109 l 1); Grade 2 diarrhoea for more
than 7 days despite optimal treatment with anti-diarrhoeals; Grade
4 thrombocytopenia forX5 days or associated with active bleeding
or requiring platelet transfusion; any other Grade 3 or 4 non-
haematological toxicity excluding Grade 3 nausea, Grade 3 or 4
diarrhoea or vomiting in patients who had not received optimal
treatment, Grade 3 fatigue (unless there was an increase by at least
two grades from baseline) or transient asymptomatic Grade 3
biochemical abnormalities. Later in the trial (from June 2015
during recruitment to the 40mg bi-daily (b.d.) cohort), treatment-
related AEs of any grade which together prevented administration
of more than 25% of planned doses of AZD0424 during Cycle 1
were also considered dose-limiting. The MTD was defined as the
dose below the dose level in which two out of up to six patients in a
cohort experienced a DLT in the first cycle of AZD0424.
The study was conducted in accordance with the Declaration of
Helsinki and the International Conference on Harmonisation of
Good Clinical Practice Guidelines and approved by relevant
regulatory and independent ethics committees.
Patient evaluation. All patients receiving at least one dose of
AZD0424 were evaluable for safety and efficacy analyses. Safety
and tolerability of AZD0424 were assessed according to NCI
CTCAE version 4.02. Patients who were withdrawn from
treatment, or received less than 75% of the planned doses of
AZD0424 during the first cycle, for reasons other than toxicity
were not evaluable for dose review decisions and could be replaced.
Disease response was assessed according to RECIST 1.1. For stable
disease (SD), follow-up measurements had to meet the SD criteria
at least once at least 6 weeks after the first dose of AZD0424.
Dose modifications and delays. Treatment interruptions of up to
2 weeks were permitted for toxicities of Grade 2 or higher related
to AZD0424 to allow resolution of toxicity topGrade 1 or to meet
the eligibility criteria. Dose reductions to the previous dose level
were permitted to manage toxicities.
Pharmacokinetic analysis. Patients were fasted for 3 h prior to
administration of AZD0424. Blood samples for analysis of plasma
levels of AZD0424 were taken at the following time points: Cycle 1:
Pre-dose and at 0.5, 1, 2, 4, 6 and 10 h post-dose on Day 1, then at
24 and 48 h and pre-dose on Days 8, 15 and 22; Cycle 2 (Day 29):
Pre-dose and at 0.5, 1, 2, 4, 6, 10, 24 and 48 h. For patients
receiving twice-daily AZD0424, the timing of samples was in
relation to the morning dose of the drug. Plasma was isolated from
centrifuged blood samples and stored at  80 1C prior to
quantification of AZD0424 by a validated high performance liquid
chromatography method with mass spectrometric detection.
Plasma concentration/time data were analysed using non-com-
partmental methods.
Pharmacodynamic analysis. Src inhibition is known to reduce
bone resorption, resulting in a decrease in urinary N-terminal
cross-linking telopeptides of type I collagen (NTX) and serum
C-terminal cross-linking telopeptides of type I collagen (CTX)
(Hannon et al, 2012). Measurements of urinary NTX and serum
CTX levels were performed before the first administration of
AZD0424 and then weekly, at the same time of day, for up to 6
weeks following first administration as markers of Src inhibition.
Samples were analysed at the Mellanby Centre for Bone Research
in Sheffield using the Cobas e411 automated immunoassay (Roche
Diagnostics, Mannheim, Germany) for serum CTX (ngml 1), and
the Ortho Clinical Diagnostics (High Wycombe, UK) automated
immunoassay for urine NTX. Urinary NTX measurements were
reported as a ratio to urinary creatinine (nmol bone collagen
equivalent (BCE)/mmol creatinine). Tumour biopsies for measure-
ment of tumour biomarkers (p-Src, Ki67, p-PAX, and p-FAK) by
immunohistochemical staining were optional.
RESULTS
Patient characteristics. A total of 43 patients were enrolled in the
study between 25 October 2012 and 18 November 2015 at three
UK Experimental Cancer Medicine Centres, of whom 41 received
AZD0424. Baseline characteristics are summarised in Table 1.
Nineteen dosed patients (46.3%) had colorectal cancer while the
remainder had a range of other solid tumours. All 41 patients had
RECIST measurable disease at baseline and 90% of patients had
more than one site of disease involvement. All patients enrolled
onto the study had received prior chemotherapy and most were
heavily pre-treated.
Table 1. Summary of baseline demographic and disease
characteristics (N¼41 patients)
Age, median (range)
Years 59 (38–76)
Gender, n(%)
Male 22 (54)
Female 19 (46)
Performance status, n(%)
0 15 (37)
1 25 (61)
2 1 (2)
Primary tumour type, n(%)
Colorectal 19 (46)
Lung 3 (7)
Pancreas 2 (5)
Bile duct 2 (5)
Cervical 2 (5)
Breast 2 (5)
Anal 2 (5)
Othera 9 (22)
Disease sites at study entry, n(%)
Liver metastases 27 (66)
Lung metastases 25 (61)
Lymph nodes 21 (51)
Peritoneal metastases 13 (32)
Soft tissue 7 (17)
Bone metastases 3 (7)
Otherb 22 (54)
Prior treatment, n(%)
Chemotherapy 41 (100)
No. regimens 1–3 24 (59)
4–6 15 (37)
X7 2 (5)
Surgery 33 (80)
Radiotherapy 17 (41)
aLower oesophagus (1), SCC cheek (1), epithelioid mesothelioma (1), GIST (1), ocular
melanoma (1), ovary (1), peritoneal carcinoma (1), pleura (1), unknown primary (1).
bLocal recurrence (3), malignant pleural effusion (1), primary tumour (6), other metastases
(12).
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Dose escalation and MTD. The dose levels explored, number of
patients treated and DLTs are summarised in Table 2. Expansion
to three-patient cohorts occurred at 20mg per day triggered by
Grade 2 hypophosphataemia possibly related to AZD0424. Further
escalation continued (see Supplementary Information) until two
patients experienced DLTs (Grade 3 maculopapular rash, and
Grade 3 fatigue, anorexia and maculopapular rash) in the 150mg
cohort leading to this cohort being declared non-tolerated. With
one DLT (Grade 3 diarrhoea and melaena) at 120mg o.d. in an
expanded patient cohort, this was declared the MTD. Given that
considerable drug-related toxicity was seen at this level, twice daily
dosing of AZD0424 at 40mg b.d. was explored, but two DLTs
occurred at 40mg b.d. and this was less well tolerated than 80mg
o.d., so b.d. dosing was not investigated further.
AZD0424 administration, safety and tolerability. A total of 82
cycles of AZD0424 treatment were administered with patients on
treatment for a median of 45 days (range 4–182 days). Fifteen
patients were withdrawn from the study prior to completing one
cycle of treatment. Six patients were withdrawn due to AEs or
SAEs, four due to disease progression and five due to other reasons
(patient request¼ 3; interruption of treatment42 weeks unrelated
to AZD0424¼ 1; and combination of progressive disease (PD) and
several AEs/SAEs¼ 1). Twenty-six patients (63.4%) had dose
delays and/or alterations during the study; however, overall
treatment compliance was satisfactory with 68% of patients
receiving X75% of their planned treatment in Cycle 1 and 39%
of these receiving 100% of their planned treatment.
Of the 41 patients treated, 38 (92.7%) experienced at least one
AE that was considered possibly, probably or highly probably
related to AZD0424, and 17 patients (41.5%) had at least one
AZD0424-related event that was Grade 3–5 in severity. The mean
number of treatment-related AE episodes per patient and the
number of treatment-related Grade 3, 4 or 5 AEs increased
markedly at doses above 60mg per day (Table 2). Nausea, fatigue,
anorexia and alopecia were the most commonly reported
treatment-related AEs, each occurring in 440% of patients
(Table 3). Hypophosphataemia was the most commonly observed
laboratory abnormality of any cause seen during the study, with
changes in calcium levels also apparent but less marked. A decline
in lymphocyte count was observed in 28/41 patients (68.3%) but
was not associated with an apparent increase in infections.
Four patients died within 4 weeks of the last AZD0424
administration, all of whom had withdrawn from the study before
completion of one cycle of AZD0424. Two of these deaths were due
to disease progression, and two were due to pneumonia. One death
due to pneumonia was considered possibly related to AZD0424.
Pharmacokinetics. When given o.d., AZD0424 was cleared from
plasma with a mean terminal half-life (t1/2) of 8.4±2.8 h
(mean±s.d.) (Supplementary Table 1). Linear, dose-dependent
increases in maximum concentration (Cmax) and the area under
the concentration-time curve from 0–24 h (AUC(0-24 h)) were seen
(Figure 2A), while the time to reach maximum concentration
(Tmax) was independent of dose and under 2 h in almost all
Table 2. Dose levels, dose limiting toxicities and AZD0424-related AE episodes
Cohort
AZD0424
dose mg
Patients
treated
Total cycles
AZD0424
started
Patients
evaluable
Patients
experiencing
DLT
Description of DLT
Related AE
episodes per
patient
(mean (range))
Related Grade 3–5
AE episodes per
patient
(mean (range))
1 5mg o.d. 1 2 1 0 2.0 (2 to 2) 0
2 10mg o.d. 1 7 1 0 5.0 (5 to 5) 0
3 20mg o.d. 4 9 3 0 7.33 (6 to 9) 0
4 40mg o.d. 4 13 3 0 4.50 (1 to 7) 1.0 (1 to 1)
5 60mg o.d. 3 5 3 0 4.0 (4 to 4) 1.0 (1 to 1)
6 80mg o.d. 3 5 3 0 9.50 (5 to 14) 0
7 120mg o.d. 11 19 7 1 G3 diarrhoea and
melaena
8.90 (3 to 19) 2.50 (1 to 4)
8 150mg o.d. 7 11 5 2 G3 maculopapular rash
G3 fatigue, anorexia and
maculopapular rash
10.14 (1 to 22) 3.0 (1 to 8)
9 40mg b.d. 7 11 6 2 G3 fatigue
Completed o75% of
Cycle 1 doses due to
combination G2 nausea,
fatigue, and anorexia
12.29 (5 to 17) 2.75 (2 to 4)
Abbreviations: AE¼ adverse event; b.d.=bi-daily; DLT¼dose-limiting toxicity; o.d.=once-daily.
Table 3. Treatment-related AEs by NCI-CTCAE Grade v4.02
AE (occurring in 410% of
patients)
All grades
patients n (%)
Grade 3–5
patients n (%)
Nausea 27 (66) 2 (5)
Fatigue 21(51) 5 (12)
Anorexia 19 (46) 1 (2)
Alopecia 17 (41) 0
Hypophosphataemia 16 (39) 8 (20)
Dysgeusia 14 (34) 0
Vomiting 13 (32) 1 (2)
Diarrhoea 12 (29) 2 (5)
Lymphocyte count decreased 10 (24) 5 (12)
Maculopapular rash 9 (22) 2 (5)
Pruritis 7 (17) 0
Anaemia 7 (17) 3 (7)
Constipation 6 (15) 1 (2)
Headache 5 (12) 0
Aspartate aminotransferase increased 5 (12) 0
Abbreviation: AE¼ adverse event. Other XG3 treatment-related AEs occurring in any
patient (n) – G3 neutrophil count decreased (1), G3 lower gastrointestinal haemorrhage (1),
G3 melaena (1), G5 lung infection (1), G3 chest infection (1), G3 hyponatraemia (1), G3 acute
kidney injury (1).
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patients (Figure 2B). Both Cmax and AUC(0-24 h) were much higher
for AZD0424 than saracatinib at comparable doses (Baselga et al,
2010) (Supplementary Figure 1). t1/2 and AUC could not be
accurately determined for the b.d. cohort as the sampling schedule
did not capture sufficient data before the second daily dose.
Despite a greater number of AEs experienced by individual
patients at higher dose levels, no clear relationships could be
discerned between any PK parameter and individual AEs, with the
possible exception of hypophosphataemia where Grade 2 or 3
hypophosphataemia appeared to be more frequent in patients with
minimum concentration levels (Cmin)X200 nM (data not shown).
Pharmacodynamics. No significant post-administration changes
in CTX or NTX level were observed in the single patient who
received AZD0424 5mg. In all other cohorts, a fall relative to
baseline values in both CTX and NTX was observed by week 2 and
maintained to 7 weeks (Figure 3). Greater percentage reductions in
CTX and NTX levels were seen at doses of more than 10mg per
day of AZD0424 than that achieved with 50mg per day of
saracatinib and for NTX, similar to that achieved with 125 or
175mg per day of saracatinib (Hannon et al, 2012) (Figure 3). No
patients consented to undergo a tumour biopsy during the study.
Efficacy. No patients who received AZD0424 achieved a complete
response or partial response. A total of seven patients (17.1%) had
a best response of SD (lasting at least 6 weeks), of whom five
achieved SD lasting 412 weeks. Twenty-two patients had a best
response of PD and 12 patients had no tumour response recorded.
There were no obvious shared characteristics among the patients
who experienced SD.
DISCUSSION
In this study AZD0424 was evaluated as monotherapy at total daily
doses ranging from 5mg to 150mg in 41 patients with advanced
solid tumours. PK data indicated rapid absorption and high
bioavailability with dose-dependent, linear increases in Cmax and
AUC. Clear inhibition of bone turnover was achieved with
AZD0424 doses of 20mg per day or more, indicating that almost
all the patients in the study received AZD0424 doses that achieved
Src target inhibition. Both plasma drug concentrations and
reductions in markers of bone turnover were considerably higher
with AZD0424 than those seen in phase I trials of the closely
related Src inhibitor saracatinib at similar doses.
The toxicity profile of AZD0424 was generally consistent with
expectations based on non-clinical studies of AZD0424 and clinical
data for other Src/ABL inhibitors. Gastrointestinal disorders were
the most frequently observed AZD0424-related toxicities including
nausea, anorexia and vomiting. A similar profile of toxicities was
observed with saracatinib but the grade and frequency of these
findings was lower than found with AZD0424 (Baselga et al, 2010).
Hypophosphataemia was also common with AZD0424, with eight
patients (19.5%) experiencing an AE of Grade 3 hypopho-
sphataemia related to the drug. This is relatively high compared
with most other saracatinib monotherapy studies where this
finding was rare or absent (Baselga et al, 2010; Gucalp et al, 2011;
Gangadhar et al, 2013), although a 50% rate of Grade 3
hypophosphataemia was reported in a phase II trial of this agent
in colorectal cancer patients (Reddy et al, 2015). The investigators
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Figure 2. Pharmacokinetic data for once daily dosing of AZD0424. (A)
Relationship between AZD0424 dose and peak concentration (Cmax)
and AUC(0–24h) for Cycle 1. (B) Relationship between AZD0424 dose
and time to reach peak concentration (Tmax) for Cycle 1.
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Figure 3. (A) CTX levels over time, expressed as a percentage of
baseline levels. (B) NTX levels over time, expressed as a percentage of
baseline levels. Published data for saracatinib are also shown (black
edged diamonds labelled ‘Sara’) (Hannon et al, 2012). b.d.=bi-daily;
o.d.=once-daily.
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postulated that the presence of malignancy involving the gastro-
intestinal tract might have rendered colorectal patients particularly
sensitive to this phenomenon; however, our study showed no
apparent predisposition to hypophosphataemia with AZD0424 for
colorectal cancer patients. Greater exposure was found with
AZD0424 at a dose of 20mg than observed with saracatinib at
its recommended phase II dose (RP2D) of 175mg (Baselga et al,
2010). As saracatinib and AZD0424 have a similar potency for Src
inhibition, this greater exposure to AZD0424 may have led to a
greater degree of Src inhibition and more extensive off-target
kinase inhibition than found with the former agent. No clear
correlations were seen between any individual AEs and PK
parameters. This may be explained by a threshold effect once a
certain degree of Src inhibition is achieved or by the lack of data
points at lower doses.
Based on the DLTs and AEs observed during this study, the
protocol-defined RP2D for AZD0424 would be 80mg o.d.;
however, in practice this may not be suitable for long-term dosing
based on the burden of Grade 1 and 2 AEs. This phenomenon of
cumulative low grade toxicity is increasingly recognised with the
use of molecularly targeted agents and there are calls for DLT
criteria to be adapted accordingly (Postel-Vinay et al, 2014), for
example to include any drug-related toxicity that prevents
administration of 475% of planned doses within the first cycle
as a DLT, and for relative dose intensity to be factored into
determination of the RP2D. Given that clear pharmacodynamic
effects on bone turnover were seen at relatively low doses of
AZD0424, the question also arises as to the appropriateness of
using the traditional model of dose escalation to the MTD in phase
I clinical trials of molecularly targeted agents. While for
chemotherapeutic agents, greatest efficacy has historically been
seen predominantly at higher doses close to the RP2D (Von Hoff
and Turner, 1991), more recent data suggest that this does not
necessarily hold true for molecularly targeted agents with patients
treated at lower doses experiencing efficacy outcomes no worse
than those treated at higher doses (Jain et al, 2010). Indeed, the
importance and need to determine the MTD of novel agents in the
era of biomarker-driven research is the subject of debate (Haines,
2008; Sleijfer and Wiemer, 2008). Given the potential for loss of
kinase selectivity as doses increase, and that increased toxicity at
higher doses of AZD0424 in this study significantly limited
tolerability, it is possible that the minimal biologically effective
dose might have been a more clinically relevant parameter than
MTD.
Despite the pharmacodynamic evidence of Src target inhibition
by AZD0424, there was no evidence of anti-tumour activity in this
study. As no tumour biopsies were available, we were unable to
analyse the Src status of the patients recruited to determine whether
any patients had disease that might be expected to be responsive to
Src inhibition. The rate of PD (22/41, 53.7%) was comparable to that
seen in other published phase I studies (Horstmann et al, 2005;
Italiano et al, 2008; Wong et al, 2016), which is typically around
50%. A significant number of patients left the study before the first
disease assessment at 6 weeks. Seven patients (17.1%) had
documented SD, a figure similar to that found in the phase I trial
of saracatinib (Baselga et al, 2010). Concerns were raised about the
rate of disease progression in two individual patients dosed at 40mg
b.d. and 150mg o.d. One other patient (treated with 40mg b.d.)
experienced a rapid clinical decline that reversed on cessation of
treatment. A detailed review of individual patient and overall trial
data found no convincing evidence to suggest that AZD0424 was
accelerating the rate of disease progression. It did, however, suggest
that the cumulative lower grade toxicities experienced by patients
taking AZD0424 at higher dose levels may have contributed to
deteriorating clinical condition.
Based on the lack of efficacy seen in this study, further
evaluation of AZD0424 monotherapy in patients with solid
tumours is not recommended. Combination dosing with other
agents might require further dose reduction of AZD0424 in order
to be tolerable; however, emergent data from pre-clinical work
have failed to show sufficient promising evidence of synergy for
AZD0424 with other agents to warrant further investigation.
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